| Year |
Title |
Altmetric |
| 2022
|
Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation (Nature, (2022), 609, 7929, (1021-1028), 10.1038/s41586-022-05215-w).
Nature.
612:E12.
2022
|
|
| 2022
|
Failure of human rhombic lip differentiation underlies medulloblastoma formation.
Nature.
609:1021-1028.
2022
|
|
| 2022
|
Glioma progression is shaped by genetic evolution and microenvironment interactions.
Cell.
185:2184-2199.e16.
2022
|
|
| 2022
|
Mice lacking full length Adgrb1 (Bai1) exhibit social deficits, increased seizure susceptibility, and altered brain development.
Experimental Neurology.
351.
2022
|
|
| 2021
|
Ten-eleven translocation protein 1 modulates medulloblastoma progression.
Genome Biology.
22.
2021
|
|
| 2021
|
The transcriptional landscape of Shh medulloblastoma.
Nature Communications.
12.
2021
|
|
| 2021
|
Subgroup and subtype-specific outcomes in adult medulloblastoma.
Acta Neuropathologica.
142:859-871.
2021
|
|
| 2021
|
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Oncogene.
40:5182-5191.
2021
|
|
| 2021
|
N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.
Journal of Clinical Investigation.
131.
2021
|
|
| 2021
|
Analysis of morphological characteristics of IDH-mutant/wildtype brain tumors using whole-lesion phenotype analysis.
NOA.
3.
2021
|
|
| 2020
|
The advent of precision epigenetics for medulloblastoma..
Oncoscience.
7:47-48.
2020
|
|
| 2020
|
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.
Cell Reports Medicine.
1.
2020
|
|
| 2020
|
A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific Apoptosis.
Clinical Cancer Research.
26:2711-2724.
2020
|
|
| 2020
|
Pan-cancer analysis of whole genomes.
Nature.
578:82-93.
2020
|
|
| 2020
|
Correction: EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway (Oncogene, (2020), 39, 5, (1041-1048), 10.1038/s41388-019-1036-7).
Oncogene.
39:1165.
2020
|
|
| 2020
|
EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.
Oncogene.
39:1041-1048.
2020
|
|
| 2019
|
Longitudinal molecular trajectories of diffuse glioma in adults.
Nature.
576:112-120.
2019
|
|
| 2019
|
A simple genotyping method to detect small CRISPR-Cas9 induced indels by agarose gel electrophoresis.
Scientific Reports.
9.
2019
|
|
| 2019
|
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma.
Nature.
574:707-711.
2019
|
|
| 2019
|
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma..
Nature.
574:707-711.
2019
|
|
| 2019
|
Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023)).
Immunity.
51:411-412.
2019
|
|
| 2019
|
Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.
American Journal of Ophthalmology.
203:117-118.
2019
|
|
| 2019
|
Arylsulfonamide 64B inhibits hypoxia/ HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.
Clinical Cancer Research.
25:2206-2218.
2019
|
|
| 2019
|
The expanding functional roles and signaling mechanisms of adhesion g protein–coupled receptors.
Annals of the New York Academy of Sciences.
1456:5-25.
2019
|
|
| 2018
|
Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.
Clinical Cancer Research.
24:6471-6482.
2018
|
|
| 2018
|
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Cell Reports.
25:1304-1317.e5.
2018
|
|
| 2018
|
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.
Cell Systems.
7:422-437.e7.
2018
|
|
| 2018
|
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
Cancer Cell.
34:211-224.e6.
2018
|
|
| 2018
|
Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060)).
Cell.
174:1034-1035.
2018
|
|
| 2018
|
Erratum: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)).
Cell Reports.
23:3698.
2018
|
|
| 2018
|
Glioma through the looking GLASS: Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.
Neuro-Oncology.
20:873-884.
2018
|
|
| 2018
|
BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation.
Cancer Cell.
33:1004-1016.e5.
2018
|
|
| 2018
|
The Immune Landscape of Cancer.
Immunity.
48:812-830.e14.
2018
|
|
| 2018
|
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Cancer Cell.
33:690-705.e9.
2018
|
|
| 2018
|
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
Cancer Cell.
33:721-735.e8.
2018
|
|
| 2018
|
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
Cancer Cell.
33:676-689.e3.
2018
|
|
| 2018
|
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
Cancer Cell.
33:706-720.e9.
2018
|
|
| 2018
|
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
Cell.
173:386-399.e12.
2018
|
|
| 2018
|
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell.
173:400-416.e11.
2018
|
|
| 2018
|
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Cell.
173:291-304.e6.
2018
|
|
| 2018
|
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell.
173:371-385.e18.
2018
|
|
| 2018
|
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
Cell.
173:338-354.e15.
2018
|
|
| 2018
|
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Cell.
173:321-337.e10.
2018
|
|
| 2018
|
Pathogenic Germline Variants in 10,389 Adult Cancers.
Cell.
173:355-370.e14.
2018
|
|
| 2018
|
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Cell.
173:305-320.e10.
2018
|
|
| 2018
|
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Cell Reports.
23:227-238.e3.
2018
|
|
| 2018
|
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Cell Reports.
23:239-254.e6.
2018
|
|
| 2018
|
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Cell Reports.
23:194-212.e6.
2018
|
|
| 2018
|
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Cell Reports.
23:213-226.e3.
2018
|
|
| 2018
|
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Cell Reports.
23:172-180.e3.
2018
|
|
| 2018
|
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
Cell Reports.
23:255-269.e4.
2018
|
|
| 2018
|
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
Cell Reports.
23:297-312.e12.
2018
|
|
| 2018
|
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
Cell Reports.
23:282-296.e4.
2018
|
|
| 2018
|
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
Cell Reports.
23:181-193.e7.
2018
|
|
| 2018
|
Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Cell Reports.
23:270-281.e3.
2018
|
|
| 2018
|
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Cell Reports.
23:313-326.e5.
2018
|
|
| 2018
|
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Cell Systems.
6:282-300.e2.
2018
|
|
| 2018
|
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
Cell Systems.
6:271-281.e7.
2018
|
|
| 2018
|
Taking a HIF pill for old age diseases?.
Aging.
10:290-292.
2018
|
|
| 2017
|
Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example..
Bio-protocol.
7.
2017
|
|
| 2017
|
Cancer therapy: Neutrophils traffic in cancer nanodrugs.
Nature Nanotechnology.
12:616-618.
2017
|
|
| 2017
|
Intertumoral Heterogeneity within Medulloblastoma Subgroups.
Cancer Cell.
31:737-754.e6.
2017
|
|
| 2017
|
BAI1 orchestrates macrophage inflammatory response to HSV infection-implications for oncolytic viral therapy.
Clinical Cancer Research.
23:1809-1819.
2017
|
|
| 2017
|
Overcoming therapeutic resistance in glioblastoma: The way forward.
Journal of Clinical Investigation.
127:415-426.
2017
|
|
| 2017
|
A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis.
Oncotarget.
8:99245-99260.
2017
|
|
| 2017
|
Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility
2017
|
|
| 2017
|
Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.
Bioorganic and Medicinal Chemistry Letters.
27:1731-1736.
2017
|
|
| 2017
|
Two new species of betatorqueviruses identified in a human melanoma that metastasized to the brain.
Oncotarget.
8:105800-105808.
2017
|
|
| 2016
|
Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase.
Clinical Cancer Research.
22:6256-6265.
2016
|
|
| 2016
|
Adhesion GPCRs in tumorigenesis.
Handbook of experimental pharmacology.
234:369-396.
2016
|
|
| 2016
|
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis.
Journal of Clinical Oncology.
34:2468-2477.
2016
|
|
| 2016
|
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
2016
|
|
| 2016
|
Divergent clonal selection dominates medulloblastoma at recurrence.
Nature.
529:351-357.
2016
|
|
| 2016
|
A role for activated Cdc42 in glioblastoma multiforme invasion.
Oncotarget.
7:56958-56975.
2016
|
|
| 2016
|
BAI1: From cancer to neurological disease.
Oncotarget.
7:17288-17289.
2016
|
|
| 2015
|
Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.
New England Journal of Medicine.
372:2481-2498.
2015
|
|
| 2015
|
BAI1 regulates spatial learning and synaptic plasticity in the hippocampus.
Journal of Clinical Investigation.
125:1497-1508.
2015
|
|
| 2015
|
Biology of advanced uveal melanoma and next steps for clinical therapeutics.
Pigment Cell and Melanoma Research.
28:135-147.
2015
|
|
| 2015
|
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Genome Research.
25:316-327.
2015
|
|
| 2014
|
Human brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.
Cancer Research.
74:4536-4548.
2014
|
|
| 2014
|
Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)).
Cell.
157:753.
2014
|
|
| 2014
|
Cytogenetic prognostication within medulloblastoma subgroups.
Journal of Clinical Oncology.
32:886-896.
2014
|
|
| 2014
|
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway.
Cancer Research.
74:1371-1378.
2014
|
|
| 2014
|
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex..
Molecular Cell.
53:534-548.
2014
|
|
| 2014
|
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Acta Neuropathologica Communications.
2.
2014
|
|
| 2014
|
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Oncotarget.
5:9703-9709.
2014
|
|
| 2013
|
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
Acta Neuropathologica.
126:917-929.
2013
|
|
| 2013
|
miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development.
PLoS One.
8.
2013
|
|
| 2013
|
The somatic genomic landscape of glioblastoma.
Cell.
155:462.
2013
|
|
| 2013
|
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Journal of Clinical Oncology.
31:2927-2935.
2013
|
|
| 2013
|
Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.
Journal of Biological Chemistry.
288:22248-22256.
2013
|
|
| 2013
|
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Future Medicinal Chemistry.
5:553-572.
2013
|
|
| 2013
|
Design, synthesis and evaluation of the cytotoxicity of a N-mustard and paclitaxel conjugate prodrug.
Journal of Chinese Pharmaceutical Sciences.
22:137-143.
2013
|
|
| 2012
|
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
Clinical Cancer Research.
18:6623-6633.
2012
|
|
| 2012
|
A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40kDa vasculostatin from tumor suppressor BAI1.
Oncogene.
31:5144-5152.
2012
|
|
| 2012
|
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Journal of Molecular Medicine.
90:1161-1171.
2012
|
|
| 2012
|
KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology.
PLoS One.
7.
2012
|
|
| 2012
|
Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor.
ACS Medicinal Chemistry Letters.
3:620-625.
2012
|
|
| 2012
|
Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl-2 H -chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.
Journal of Medicinal Chemistry.
55:6738-6750.
2012
|
|
| 2012
|
Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
Nature.
487:49-56.
2012
|
|
| 2012
|
Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl) methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.
Bioorganic and Medicinal Chemistry.
20:4590-4597.
2012
|
|
| 2012
|
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.
American Journal of Pathology.
180:2108-2119.
2012
|
|
| 2012
|
P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3.
Journal of Clinical Investigation.
122:1283-1295.
2012
|
|
| 2012
|
5-D confocal imaging to visualize glioblastoma spheroid invasion into the extracellular matrix.
Microscopy and Microanalysis.
18:180-181.
2012
|
|
| 2012
|
Glioblastoma cancer stem-like cells: Implications for pathogenesis and treatment.
Cancer Journal.
18:100-106.
2012
|
|
| 2011
|
Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Journal of Medicinal Chemistry.
54:8471-8489.
2011
|
|
| 2011
|
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes.
IEEE Transactions on Biomedical Engineering.
58:3469-3474.
2011
|
|
| 2011
|
Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.
Bioorganic and Medicinal Chemistry Letters.
21:5528-5532.
2011
|
|
| 2011
|
Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI.
Cancer Research.
71:5859-5870.
2011
|
|
| 2011
|
Proteomics of gliomas: Initial biomarker discovery and evolution of technology.
Neuro-Oncology.
13:926-942.
2011
|
|
| 2011
|
At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop.
Journal of Molecular Medicine.
89:91-94.
2011
|
|
| 2011
|
A conspiracy of glioma and endothelial cells to invade the normal brain.
Oncotarget.
2:1-4.
2011
|
|
| 2011
|
Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development.
Journal of Molecular Medicine.
89:743-752.
2011
|
|
| 2010
|
An integrative approach for in silico glioma research.
IEEE Transactions on Biomedical Engineering.
57:2617-2621.
2010
|
|
| 2010
|
Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma.
CA: A Cancer Journal for Clinicians.
60:166-193.
2010
|
|
| 2010
|
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.
American Journal of Pathology.
176:2039-2050.
2010
|
|
| 2010
|
Natural mutagenesis of human genomes by endogenous retrotransposons.
Cell.
141:1253-1261.
2010
|
|
| 2009
|
Brain cancer propagating cells: biology, genetics and targeted therapies.
Trends in Molecular Medicine.
15:519-530.
2009
|
|
| 2009
|
Identification of a novel small molecule HIF-1α translation inhibitor.
Clinical Cancer Research.
15:6128-6136.
2009
|
|
| 2009
|
Tumor initiating cells in malignant gliomas: Biology and implications for therapy.
Journal of Molecular Medicine.
87:363-374.
2009
|
|
| 2009
|
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Cancer Research.
69:2540-2549.
2009
|
|
| 2009
|
Stat3 activation is required for the growth of U87 cell-derived tumours in mice.
European Journal of Cancer.
45:677-684.
2009
|
|
| 2009
|
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.
Cancer Research.
69:1212-1220.
2009
|
|
| 2008
|
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature.
455:1061-1068.
2008
|
|
| 2008
|
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Cancer Research.
68:6953-6962.
2008
|
|
| 2008
|
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment.
Molecular Therapy.
16:599-606.
2008
|
|
| 2007
|
Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)).
Cancer Research.
67:8422-8423.
2007
|
|
| 2007
|
Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4.
Cancer Research.
67:6872-6881.
2007
|
|
| 2007
|
Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors.
PLoS One.
2.
2007
|
|
| 2007
|
Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.
Journal of Proteome Research.
6:559-570.
2007
|
|
| 2006
|
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.
Cancer Research.
66:11991-11997.
2006
|
|
| 2006
|
Proteomic identification of the wt-p53-regulated tumor cell secretome.
Oncogene.
25:7650-7661.
2006
|
|
| 2006
|
Inhibitors of hypoxia-inducible factor-1 signaling
2006
|
|
| 2006
|
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.
Proteomics.
6:6277-6287.
2006
|
|
| 2006
|
Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration.
Clinical Cancer Research.
12:6331-6336.
2006
|
|
| 2006
|
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms.
Cancer Research.
66:7067-7074.
2006
|
|
| 2006
|
'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.
Journal of Neuropathology and Experimental Neurology.
65:529-539.
2006
|
|
| 2006
|
Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy.
Clinical Cancer Research.
12:2716-2729.
2006
|
|
| 2005
|
Hypoxia inducible factor-1: A novel target for cancer therapy
2005
|
|
| 2005
|
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.
Oncogene.
24:3632-3642.
2005
|
|
| 2005
|
Cancer scene investigation: How a cold virus became a tumor killer.
Future Oncology.
1:247-258.
2005
|
|
| 2005
|
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
Neuro-Oncology.
7:134-153.
2005
|
|
| 2005
|
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.
Neuro-Oncology.
7:122-133.
2005
|
|
| 2005
|
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
Cancer Research.
65:1406-1413.
2005
|
|
| 2005
|
Functional evolution of ADAMTS genes: Evidence from analyses of phylogeny and gene organization.
BMC Ecology and Evolution.
5.
2005
|
|
| 2005
|
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
Cancer Research.
65:605-612.
2005
|
|
| 2004
|
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Clinical Cancer Research.
10:8603-8612.
2004
|
|
| 2004
|
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.
Laboratory Investigation.
84:397-405.
2004
|
|
| 2004
|
Genetic and hypoxic regulation of angiogenesis in gliomas.
Journal of Neuro-Oncology.
70:229-243.
2004
|
|
| 2004
|
Absence of KLF6 gene mutations in human astrocytic tumors and cell lines [2].
International Journal of Cancer.
111:642-643.
2004
|
|
| 2004
|
Use of replicating oncolytic adenoviruses in combination therapy for cancer.
Clinical Cancer Research.
10:5299-5312.
2004
|
|
| 2004
|
Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.
Clinical Cancer Research.
10:5187-5201.
2004
|
|
| 2004
|
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia
2004
|
|
| 2004
|
Opening the chamber of peer-review secrets [2].
Nature.
429:803.
2004
|
|
| 2004
|
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion
2004
|
|
| 2004
|
PIKE (Phosphatidylinositol 3-Kinase Enhancer)-A GTPase Stimulates Akt Activity and Mediates Cellular Invasion.
Journal of Biological Chemistry.
279:16441-16451.
2004
|
|
| 2004
|
Emerging molecular therapies for brain tumors..
Seminars in Oncology.
31:38-46.
2004
|
|
| 2004
|
Replicative oncolytic herpes simplex viruses in combination cancer therapies
2004
|
|
| 2004
|
Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population.
Cancer Research.
64:920-927.
2004
|
|
| 2004
|
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma.
American Journal of Pathology.
165:1151-1161.
2004
|
|
| 2003
|
Inactivation of Wild-Type p53 Protein Function by Reactive Oxygen and Nitrogen Species in Malignant Glioma Cells.
Cancer Research.
63:8670-8673.
2003
|
|
| 2003
|
Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.
Oncogene.
22:7716-7727.
2003
|
|
| 2003
|
Replicative oncolytic adenoviruses in multimodal cancer regimens.
Human gene therapy. Clinical development.
14:933-946.
2003
|
|
| 2003
|
Erratum: Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains (Gene (2002) 298 (69-77)).
Gene.
310:221.
2003
|
|
| 2003
|
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.
Oncogene.
22:2065-2072.
2003
|
|
| 2003
|
Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review)..
International Journal of Oncology.
23:857-869.
2003
|
|
| 2003
|
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.
American Journal of Pathology.
162:19-27.
2003
|
|
| 2003
|
Genetic modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors.
Frontiers in Bioscience-Landmark.
2003
|
|
| 2003
|
TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways.
Brain Pathology.
13:539-553.
2003
|
|
| 2002
|
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains..
Gene.
298:69-77.
2002
|
|
| 2002
|
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.
Oncogene.
21:4212-4219.
2002
|
|
| 2002
|
Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: Evidence for a precursor lesion.
Cancer Research.
62:2897-2905.
2002
|
|
| 2002
|
Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells.
Cancer Research.
62:2478-2482.
2002
|
|
| 2002
|
Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.
Cancer Research.
62:1191-1195.
2002
|
|
| 2002
|
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.
Advances in Anatomic Pathology.
9:24-36.
2002
|
|
| 2001
|
Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells
2001
|
|
| 2001
|
Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.
International Journal of Cancer.
94:35-43.
2001
|
|
| 2001
|
Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis.
Journal of Cellular Biochemistry.
82:619-633.
2001
|
|
| 2001
|
Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5.
Gene.
269:131-140.
2001
|
|
| 2001
|
Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas.
Oncogene.
20:1103-1109.
2001
|
|
| 2001
|
Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
Cancer Research.
61:1162-1170.
2001
|
|
| 2001
|
Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: A new world of angiogenesis research.
American Journal of Pathology.
158:789-796.
2001
|
|
| 2001
|
Thrombospondins and tumor angiogenesis.
Trends in Molecular Medicine.
7:401-407.
2001
|
|
| 2000
|
Application of advances in molecular biology to the treatment of brain tumors..
Current Oncology Reports.
2:425-433.
2000
|
|
| 2000
|
p53 gene mutation and ink4a-arf-deletion appear to be two mutually exclusive events in human glioblastoma.
Oncogene.
19:3816-3822.
2000
|
|
| 2000
|
Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells.
Journal of Experimental Medicine.
191:1789-1797.
2000
|
|
| 2000
|
Identification of the putative brain tumor antigen BF7/GE2 as the (De)toxifying enzyme microsomal epoxide hydrolase.
Cancer Research.
60:1403-1409.
2000
|
|
| 1999
|
The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
Cancer Research.
59:5479-5482.
1999
|
|
| 1999
|
Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Oncogene.
18:5870-5878.
1999
|
|
| 1999
|
Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma.
Oncogene.
18:1447-1456.
1999
|
|
| 1999
|
Cytokines and brain tumor therapy.
Eos (Rome, Italy).
19:12-18.
1999
|
|
| 1999
|
Frequent Co-alterations of TP53, p16/CDKN2A, p14(ARF), PTEN tumor suppressor genes in human glioma cell lines.
Brain Pathology.
9:469-479.
1999
|
|
| 1999
|
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Neuro-Oncology.
1:124-137.
1999
|
|
| 1999
|
p53 and the CNS: Tumors and developmental abnormalities.
Molecular Neurobiology.
19:61-77.
1999
|
|
| 1998
|
Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses.
International Journal of Cancer.
79:640-644.
1998
|
|
| 1998
|
Spectromicroscopy of boron for the optimization of boron neutron capture therapy (BNCT) for cancer.
Journal of Physics D: Applied Physics.
31:2642-2647.
1998
|
|
| 1998
|
Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas.
Oncogene.
16:3331-3335.
1998
|
|
| 1998
|
Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay.
International Journal of Cancer.
76:797-800.
1998
|
|
| 1998
|
Genetic instability leads to loss of both p53 alleles in a human glioblastoma.
Oncogene.
16:321-326.
1998
|
|
| 1998
|
"Turcot's syndrome": phenotype of brain tumors, survival and mode of inheritance..
International Journal of Cancer.
75:162-164.
1998
|
|
| 1998
|
CD44 expression and growth factors..
Frontiers in Bioscience-Landmark.
3.
1998
|
|
| 1998
|
Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and Secondary Glioblastomas.
Journal of Neuropathology and Experimental Neurology.
57:239-245.
1998
|
|
| 1998
|
Pineoblastoma presenting in familial adenomatous polyposis (FAP): Random association, FAP variant or Turcot syndrome?.
British Journal of Neurosurgery.
12:576-578.
1998
|
|
| 1998
|
p53 and brain tumors: From gene mutations to gene therapy.
Brain Pathology.
8:599-613.
1998
|
|
| 1997
|
58. Angiogenesis development during the progression of human astrocytoma.
Italian Journal of Neurological Sciences.
18:258.
1997
|
|
| 1997
|
Gene therapy for cancer: An explosion of new therapeutic strategies.
Medecine et hygiene.
55:1527-1535.
1997
|
|
| 1997
|
Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis.
Journal of Experimental Medicine.
186:1201-1212.
1997
|
|
| 1997
|
Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?.
Journal of Clinical Investigation.
99:1173-1178.
1997
|
|
| 1997
|
Brain tumor-polyposis syndrome: Two genetic diseases?.
Journal of Clinical Oncology.
15:2744-2758.
1997
|
|
| 1997
|
Fas ligond expression in glioblastoma cell lines and primary astrocytic brain tumors.
Brain Pathology.
7:863-869.
1997
|
|
| 1997
|
Identification of nude mice in tumorigenicity assays..
International Journal of Cancer.
71:310.
1997
|
|
| 1997
|
New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26.
Oncogene.
15:997-1000.
1997
|
|
| 1996
|
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [2].
Neurosurgery.
39:878-879.
1996
|
|
| 1995
|
Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system.
Journal of Neuro-Oncology.
26:191-198.
1995
|
|
| 1995
|
A simple p53 functional assay for screening cell lines, blood, and tumors
1995
|
|
| 1995
|
Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells
1995
|
|
| 1995
|
Cytokines and tumors of the central nervous system.
Glia.
15:264-288.
1995
|
|
| 1995
|
Microsatellite instability in human brain tumors.
Neurosurgery.
37:1231-1232.
1995
|
|
| 1994
|
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells..
Nature Genetics.
8:171-176.
1994
|
|
| 1994
|
Analysis of the p53 Gene and Its Expression in Human Glioblastoma Cells.
Cancer Research.
54:649-652.
1994
|
|
| 1994
|
Human astrocytomas and glioblastomas express monocyte chemoattractant protein‐1 (MCP‐1) in vivo and in vitro.
International Journal of Cancer.
58:240-247.
1994
|
|
| 1994
|
IL-6 stimulates growth and inhibits constitutive, protein synthesis- independent apoptosis of murine B-cell hybridoma 7TD1.
Cellular Immunology.
155:428-435.
1994
|
|
| 1994
|
Overexpression of p53 protein in gliomas.
No shinkei geka. Neurological surgery.
22:125-129.
1994
|
|
| 1993
|
Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-877).
Journal of Neuro-Oncology.
16:25-34.
1993
|
|
| 1993
|
Turcot's Syndrome of Glioma and Polyposis Occurs in the Absence of Germ Line Mutations of Exons 5 to 9 of the p53 Gene.
Cancer Research.
53:957-961.
1993
|
|
| 1993
|
Cytosolic pH sensitivity of an expressed human NHE-1 Na+-H+ exchanger.
American Journal of Physiology.
264.
1993
|
|
| 1993
|
Variant CD44 Adhesion Molecules Are Expressed in Human Brain Metastases but not in Glioblastomas.
Cancer Research.
53:5345-5349.
1993
|
|
| 1992
|
A novel cyclic analog of neuropeptide Y specific for the Y2 receptor
1992
|
|
| 1992
|
Differential expression of the CD44 molecule in human brain tumours.
International Journal of Cancer.
50:572-577.
1992
|
|
| 1992
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells: Despite the presence of inducing signals GM-CSF is not expressed in vivo.
Journal of Immunology.
148:3140-3146.
1992
|
|
| 1992
|
Interleukin-8 Is Produced in Neoplastic and Infectious Diseases of the Human Central Nervous System.
Cancer Research.
52:4297-4305.
1992
|
|
| 1990
|
Human Glioblastoma Cells Release Interleukin 6 in Vivo and in Vitro.
Cancer Research.
50:6683-6688.
1990
|
|
| 1990
|
Cytokine regulation of intercellular adhesion molecule-1 (ICAM-1) expression on human glioblastoma cells.
Clinical and Experimental Immunology.
81:142-148.
1990
|
|
| 1988
|
Fine structure of the vaccinia virus gene encoding the precursor of the major core protein 4 a.
Archives of Virology.
102:19-27.
1988
|
|
| 1987
|
Vaccinia virus produces late mRNAs by discontinuous synthesis.
Cell.
50:153-162.
1987
|
|
| 1986
|
Functional analysis of the 5' flanking sequence of a vaccinia virus late gene.
1986
|
|
| 1984
|
Intervening sequences in the ribosomal RNA genes of Ascaris lumbricoides: DNA sequences at junctions and genomic organization.
1984
|
|
